ICER Questions Benefit of Astellas Pharma’s Hot Flash Candidate

Fezolinetant, Astellas Pharma’s potential first-in-class treatment for menopausal hot flashes, shouldn’t cost more than $2,600 per year if approved, according to a cost-benefit analysis by the Institute for Clinical and Economic Review (ICER) based on the available trial data.
Source: Drug Industry Daily